A recent study by researchers at the Case Western Reserve School of Medicine has made an astonishing discovery that may revolutionize the way we approach dementia prevention. The research team found that semaglutide, a popular medication used to treat diabetes and aid in weight loss, could significantly lower the risk of dementia in people with type 2 diabetes (T2D).

Dementia is a devastating condition that affects millions worldwide, causing memory loss and cognitive decline. It occurs when brain cells are damaged, disrupting their connections and ultimately leading to this debilitating state. Encouragingly, studies indicate that approximately 45% of dementia cases could be prevented by addressing modifiable risk factors.

The study, published in the Journal of Alzheimer’s Disease, analyzed three years’ worth of electronic records from nearly 1.7 million T2D patients nationally. The researchers used a statistical approach that mimicked a randomized clinical trial to determine the effectiveness of semaglutide in preventing dementia.

Their findings suggest that patients prescribed semaglutide had a significantly lower risk of developing Alzheimer’s disease-related dementia compared to those taking other anti-diabetic medications, including GLP-1R-targeting medications. These results were even more pronounced in women and older adults.

Semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that decreases hunger and regulates blood sugar levels in T2D patients, has shown remarkable benefits beyond its primary use as a diabetes treatment. It also reduces the risk of cardiovascular diseases, further solidifying its potential in preventing dementia.

The study’s lead researcher, biomedical informatics professor Rong Xu, stated, “There is no cure or effective treatment for dementia, so this new study provides real-world evidence for its potential impact on preventing or slowing dementia development among at-high risk populations.”

While the findings are promising, it’s essential to note that further research through randomized clinical trials will be necessary to confirm the causal relationship between semaglutide and dementia prevention. Nevertheless, this groundbreaking study offers a glimmer of hope in the quest to combat dementia and improve the lives of millions worldwide.

The world’s plastic pollution crisis has reached alarming levels, threatening both planetary and human health. Recycling is often touted as a solution, but a new study reveals a disturbing truth: a single pellet of recycled plastic can contain over 80 different chemicals. Researchers from the University of Gothenburg and Leipzig have shown that these hazardous substances can leach into water, causing impacts on hormone systems and lipid metabolism in zebrafish larvae.

The study, which soaked plastic pellets in water for 48 hours before exposing zebrafish larvae to the resulting mixture, found increases in gene expression related to lipid metabolism, adipogenesis, and endocrine regulation. The researchers emphasized that these short leaching times and exposure periods are yet another indicator of the risks posed by chemicals in plastics.

Previous research has shown similar effects on humans, including threats to reproductive health and obesity from exposure to toxic chemicals in plastics. Some chemicals used as additives in plastics and substances that contaminate plastics can disturb hormones, with potential impacts on fertility, child development, links to certain cancers, and metabolic disorders.

“This is the main obstacle with the idea of recycling plastic,” said Professor Bethanie Carney Almroth. “We never have full knowledge of what chemicals will end up in an item made of recycled plastic. And there is also a significant risk of chemical mixing events occurring, which render the recycled plastic toxic.”

The researchers analyzed the chemicals leaching from the plastic pellets and found common plastics chemicals, including UV-stabilizers and plasticizers, as well as chemicals not used as additives, such as pesticides, pharmaceuticals, and biocides. These may have contaminated the plastics during their first use phase prior to becoming waste and being recycled.

The study’s findings have significant implications for a Global Plastics Treaty currently being negotiated under the United Nations Environmental Program. The authors stress that negotiators and decision-makers must include provisions to ban or reduce hazardous chemicals in plastics, and to increase transparency and reporting along plastics value chains.

“This work clearly demonstrates the need to address toxic chemicals in plastics materials and products across their life cycle,” said Professor Bethanie Carney Almroth. “We cannot safely produce and use recycled plastics if we cannot trace chemicals throughout production, use, and waste phases.”

The common blood test known as the triglyceride-glucose (TyG) index has long been used to detect insulin resistance. New research presented at the European Academy of Neurology Congress 2025 suggests that this simple test could also be used to predict how fast Alzheimer’s disease progresses in individuals with mild cognitive impairment.

A team of neurologists from the University of Brescia reviewed records for 315 non-diabetic patients with cognitive deficits, including 200 with biologically confirmed Alzheimer’s disease. All subjects underwent an assessment of insulin resistance using the TyG index and a clinical follow-up of 3 years. The results showed that when patients were divided according to their TyG index levels, those in the highest third of the Mild Cognitive Impairment subgroup deteriorated far more quickly than their lower-TyG peers.

The researchers found that high TyG was associated with blood-brain barrier disruption and cardiovascular risk factors, yet it showed no interaction with the APOE ε4 genotype. This suggests that metabolic and genetic risks may act through distinct pathways.

Identifying high-TyG patients could refine enrolment for anti-amyloid or anti-tau trials and prompt earlier lifestyle or pharmacological measures to improve insulin sensitivity.

“If targeting metabolism can delay progression, we will have a readily modifiable target that works alongside emerging disease-modifying drugs,” concluded Dr. Bianca Gumina.

The study aimed to fill the gap in understanding how quickly Alzheimer’s progresses by focusing on its impact during the prodromal mild cognitive impairment (MCI) stage.

This research has significant implications for individuals with mild cognitive impairment and their families, as it could provide a simple and cost-effective way to predict the pace of cognitive decline.

References: